Bone biologics corporationBBLG.US Overview
BBLG Overall Performance
BBLG AI Analysis & Strategy
BBLG Recent Performance
-3.65%
Bone biologics corporation
0.81%
Avg of Sector
-1.14%
S&P500
BBLG PowerScanner
BBLG Key Information
BBLG Valuation Metrics
BBLG Earnings Table
BBLG Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.